The Financial Times reported on Aug. 2 that Bristol-Myers Squibb BMY and AstraZeneca AZN are discussing a merger. Astra shares fell 8%, and Bristol shares were down about 1% in early trading on Aug. 3.
Why it matters: While smaller acquisitions are very common in biopharma, huge mergers have become much less common. If this deal went through, it would be the biggest in history.
- With market caps around $260 billion for Astra and $130 billion for Bristol, Astra would be the likely “acquirer” in this deal. The combined company would likely only trail Eli Lilly LLY, Johnson & Johnson JNJ, and AbbVie ABBV in size.
- Possible motivators could be complementary timing of patent cliffs, access to specific pipeline programs, and geographic diversification, though the drain from integrating businesses and potential Federal Trade Commission concerns due to the mutual oncology focus are real issues here.
The bottom line: We’re not making any changes to our fair value estimates for these wide-moat names, but we could be somewhat cautious if these plans are realized. With Bristol trading near its fair value estimate, we think there is little room for execution missteps.
- The discussions lead us to wonder whether Astra’s confidence in its ability to reach $80 billion in revenue by 2030 is faltering (we model $71 billion) and if Bristol is concerned about the risks surrounding its own key pipeline assets, including milvexian, Cobenfy, and next-generation oral multiple myeloma therapies.
- That said, Bristol’s massive 2028 patent cliff could fit well with Astra’s more limited patent exposure, and Astra could gain access to Bristol/BioNTech’s PD-L1/VEGF bispecific pumitamig as well as increased exposure to the US market.
